Clinical Data

Geneva – October 14, 2026 -- MindMaze Therapeutics (SIX: MMTX) reported that home-based rehabilitation with its MindMotion platform raised total motor-training dose by a median factor of 3.0 versus usual outpatient therapy alone, with 84% of active training completed without direct therapist supervision.

The multi-site program, run with Vibra Healthcare, was presented at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC. The data arrive ahead of the company's MindMotion Lite launch, expected by year-end 2026.

Program covered 177 episodes across four Vibra outpatient sites

The retrospective quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with neurological conditions, primarily stroke. It had no control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision.

Caesarea, Israel – October 13, 2026 -- IceCure Medical (Nasdaq: ICCM) reported 12-month objective response rates of 97.5% among 40 breast cancer patients treated with ProSense® cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026 in Maastricht, the Netherlands.

ProSense features in two scientific sessions at the Maastricht meeting

Dr. Lucía Graña-López of Lugo, Spain, presented the clinical potential of cryoablation in "Beyond Biopsy: Image-Guided Therapy in Practice," part of the session "From Target to Treatment: Breast Interventions."

Friendswood – October 13, 2026 -- Management recommendations changed in line with TissueCypher risk classifications for 96% of patients in a multi-center Barrett's esophagus cohort, according to data Castle Biosciences (Nasdaq: CSTL) is presenting at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Oct. 9-14.

The company is presenting three studies: two case reports and one multi-center cohort study. All three examine whether the molecular test adds risk information beyond histopathology.

TissueCypher and clinicopathologic scoring agreed only slightly in the multi-center cohort

The cohort study (P5192) compared TissueCypher with the Progression in Barrett's (PIB) clinicopathologic approach and found only slight agreement (Cohen's κ = 0.04). TissueCypher classified 83% of patients as low risk and 17% as intermediate/high risk. The PIB score classified 31% as low risk and 69% as intermediate/high risk.

Dublin – October 13, 2026 -- Keenova Therapeutics plc will present an exploratory analysis of the CONFIRM trial on October 12 at the American College of Gastroenterology Annual Meeting (October 9-14, 2026). The analysis covers TERLIVAZ (terlipressin) in hepatorenal syndrome-acute kidney injury (HRS-AKI) patients who are ineligible for liver transplant.

Ten-author analysis targets liver transplant-ineligible patients

The presentation is titled "Efficacy and Safety of Terlipressin in Patients With Hepatorenal Syndrome-Acute Kidney Injury Ineligible for Liver Transplant: An Exploratory Analysis of the CONFIRM Trial." Nancy Reau, MD, Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center, is the presenting author. Nine co-authors are listed, including Kavish Patidar, Kevin Regner and Nneka N. Ufere.

Laval – October 13, 2026 -- A six-month pilot of a standardized cirrhosis clinical pathway raised follow-up office visit adherence by 9.0% in relative terms, to 51.1% from 46.9%, across 4,251 patients in five community gastroenterology practices, Bausch Health Companies Inc. and its GI unit Salix Pharmaceuticals announced.

The results will be presented as a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting & Postgraduate Course, held October 9-14, 2026, in Nashville, Tennessee. The companies describe the findings as preliminary until presented and evaluated in peer-reviewed publications.

San Carlos, Calif. – October 12, 2026 -- Noah Medical's Galaxy robotic bronchoscopy platform delivered a 96.7% strict diagnostic yield in a 31-patient multi-center study, and an 89% yield with a cost-benefit ratio above 1 in a separate community hospital series, according to two data sets presented at the CHEST 2025 Annual Meeting in Chicago.

MATCH 2 study reports 100% procedural success across 31 patients

The prospective multi-center MATCH 2 study was led by Dr. Amit "Bobby" Mahajan of Inova Fairfax Medical Center in Virginia and Dr. Krish Bhadra of CHI Memorial in Tennessee. Investigators evaluated the Galaxy System's digital tomosynthesis and augmented fluoroscopy algorithms for real-time lesion localization in patients with peripheral pulmonary nodules.

Results across the 31 patients:

Jersey City – October 12, 2026 -- Subcutaneous (SC) infliximab delivered clinical remission in 71.4% of matched patients with ileum-dominant Crohn's disease at Week 54, against 51.4% for intravenous (IV) infliximab, according to a late-breaking analysis Celltrion USA will present for ZYMFENTRA (infliximab-dyyb) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee.

Matched analysis shows wider endoscopic gap for SC infliximab at Week 54

The pooled analysis used individual patient data from four infliximab registrational studies. Of 884 patients, 200 with ileal or ileocolonic Crohn's disease met eligibility criteria. They received either SC infliximab 120 mg every two weeks or IV infliximab 5 mg/kg every eight weeks. A 1:1 propensity score-matched analysis included 70 patients per arm.

SC infliximab outperformed IV infliximab on all three measures in the matched population:

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.

Retrospective analysis covers 636,525 patients on semaglutide 1 mg

The COMPETE SWITCH Cardiovascular study used Komodo Health's Healthcare Map claims database, spanning January 2018 to September 2025, to compare outcomes for patients escalating from semaglutide 1 mg to 2 mg against those switching to tirzepatide at doses up to 15 mg. The cardiovascular cohort included 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, tracked via an intention-to-treat approach for death, heart attack, and stroke.